AXSM vs. CORT, GBT, RARX, AIMT, HRMY, VTRS, UTHR, SRPT, RDY, and CTLT
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Corcept Therapeutics (CORT), Global Blood Therapeutics (GBT), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Harmony Biosciences (HRMY), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Catalent (CTLT). These companies are all part of the "medical" sector.
Axsome Therapeutics (NASDAQ:AXSM) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Axsome Therapeutics presently has a consensus target price of $121.92, indicating a potential upside of 58.83%. Corcept Therapeutics has a consensus target price of $40.10, indicating a potential upside of 26.86%. Given Axsome Therapeutics' higher possible upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than Corcept Therapeutics.
Corcept Therapeutics has a net margin of 22.38% compared to Axsome Therapeutics' net margin of -118.07%. Corcept Therapeutics' return on equity of 24.19% beat Axsome Therapeutics' return on equity.
In the previous week, Corcept Therapeutics had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 12 mentions for Corcept Therapeutics and 7 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.16 beat Corcept Therapeutics' score of 1.03 indicating that Axsome Therapeutics is being referred to more favorably in the media.
Corcept Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Axsome Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
Corcept Therapeutics received 101 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.62% of users gave Corcept Therapeutics an outperform vote while only 68.67% of users gave Axsome Therapeutics an outperform vote.
Summary
Corcept Therapeutics beats Axsome Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
